Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.

Molecular therapy : the journal of the American Society of Gene Therapy - 1 Dec 2005

Hummel Jeff L, Safroneeva Ekaterina, Mossman Karen L

Abstract excerpt

Oncolytic viruses that selectively replicate in cancer cells have been described for over 50 years. Despite the observation by several groups that multimutated herpes simplex type 1 vectors are oncolytic in a variety of murine tumor models, the oncolytic potential of ICP0 null mutants has not been described. This study characterizes a novel second-generation oncolytic herpes simplex type 1 vector null for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpesvirus 1, Human

Share to Immediate-Early Proteins

Share to Interferons

Share to Neoplasms

Share to Oncolytic Viruses

Share to Ubiquitin-Protein Ligases

Source

Identifiers

PMID: 16140040
DOI: 10.1016/j.ymthe.2005.07.533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.PMID 16140040Read ↗

Oncolytic herpes simplex virus vectors for cancer virotherapy.Semantic proximity Read ↗

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved TolerabilitySemantic proximity Read ↗

Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.Semantic proximity Read ↗

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.Semantic proximity Read ↗

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Semantic proximity Read ↗

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.Semantic proximity Read ↗

[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].Semantic proximity Read ↗

Gene therapy for mice sarcoma with oncolytic herpes simplex virus-1 lacking the apoptosis-inhibiting gene, icp34.5.Semantic proximity Read ↗

Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.Semantic proximity Read ↗

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.Semantic proximity Read ↗

Replicative oncolytic herpes simplex viruses in combination cancer therapies.Semantic proximity Read ↗

Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.